Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

Ozempic and Zepbound Makers Report Slower Aging Clocks, but Unreviewed Data Do Not Prove Patients Age Slower

Novo Nordisk and Eli Lilly say GLP-1 drugs slowed aging clocks, but the data are early and unreviewed. Here is what patients should know.

Medical Daily · 2h ago

Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI

Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.

MarketBeat · 9h ago

NVO vs. LLY: Novo’s CEO Says Confidence Is Gone. Lilly Is Winning 7 in 10 New Seniors.

Eli Lilly continues to outpace Novo Nordisk in the weight-loss market, supported by stronger patient growth and market share gains.

Barchart · Oct 5

From analysis to the latest developments in health,
read the most diverse news in one place.

Adults Newly Facing Leukemia Treatment Gain Another Pill Option as FDA Clears Jaypirca for Untreated CLL

FDA approved Lilly's Jaypirca as a first treatment for adults with CLL or SLL without 17p deletion. Here are the trial results, side effects, and costs.

Medical Daily · Oct 4

Lilly's Foundayo Pill Linked to 57% Lower Predicted Diabetes Risk in ATTAIN-1 Modeling, but No Cases Were Counted

A Lilly-funded modeling analysis tied Foundayo to a 57% lower predicted 10-year diabetes risk. No actual diabetes cases were counted in the study.

Medical Daily · Oct 3

Peer-Reviewed Retatrutide Data Show 23.4% Weight Loss in Adults with Diabetes and BMI of 35 or Higher

Full Lancet results for Lilly's retatrutide show 23.4% weight loss in adults with type 2 diabetes and a BMI of 35 or higher. The drug remains unapproved.

Medical Daily · Oct 2

Lilly's Ebglyss Cleared or Nearly Cleared Hand and Foot Eczema in 53% of Patients Versus 27% on Placebo

A Lilly-funded phase 3b trial found Ebglyss cleared or nearly cleared hand and foot eczema in 53% of patients at 16 weeks, versus 27% on placebo.

Medical Daily · Oct 2

Read news from The Economist, FT, and more,
with one subscription

Lilly's Eloralintide Plus Tirzepatide Produced 23.3% Weight Loss in Phase 2 Trial of Adults with Type 2 Diabetes

Lilly's eloralintide plus tirzepatide produced 23.3% weight loss vs 14.8% for tirzepatide alone in a Phase 2 diabetes trial. Here's the catch.

Medical Daily · Oct 2

Lilly's Foundayo Pill Matched Insulin on Heart Safety in Lancet Trial, but Its Lower Death Rate Needs Caution

Lilly's Foundayo pill met a heart-safety test against insulin in a Lancet trial. Fewer deaths were seen, but that result is secondary.

Medical Daily · Oct 2

Novo Nordisk Licenses Experimental Once-Weekly Obesity Pill From China's Hengrui in Deal Worth Up to $2.6 Billion

Novo Nordisk will pay $300 million upfront, and up to $2.6 billion in total, for Hengrui's once-weekly GLP-1/GIP pill, which has not been tested in people.

Medical Daily · Oct 1

Foundayo Pill Edged Higher-Dose Oral Semaglutide on Weight and A1C in Lilly's Indirect Type 2 Diabetes Analysis

Lilly's indirect analysis found Foundayo 17.2 mg edged oral semaglutide 25 mg on weight and A1C in type 2 diabetes, but the gaps were modest.

Medical Daily · Oct 1

Retatrutide Diabetes Results, Mounjaro Heart Data, and Wegovy Pill Switching Study Lead EASD 2026 Meeting Opening in Milan

EASD 2026 opens in Milan with retatrutide, Mounjaro heart, and Wegovy pill data due this week. Here is the schedule and what the numbers show.

Medical Daily · Sep 28

Once-Weekly Insulin Onswik Approved for Adults with Type 2 Diabetes but Not Recommended for Type 1 Patients

The FDA approved Onswik, a once-weekly insulin for type 2 diabetes, but not for type 1. What the trials showed and the side effects to know.

Medical Daily · Sep 27

‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event

Critics say partnership between Mounjaro maker Eli Lilly and fashion giant suggests thinness is an aspiration

The Guardian - UK · Sep 27

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times · Sep 26

Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India

Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.

International Business Times UK · Sep 24

700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient

Eli Lilly says 700,000 US seniors started GLP-1 treatment through Medicare's Bridge scheme, with taxpayers covering about $195 per patient each month.

MarketBeat · Sep 23

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Barchart · Sep 21

Eli Lilly vs. Novo: The Obesity-Drug Battle Is Entering Its Next Round

The obesity drug market is moving to the second phase, and only one appears to be better positioned to lead the second wave.

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times · Sep 21

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is…

Medical Daily · Sep 10

Two Drugmakers Paid More Than a Quarter Million American Prescribers as Weight Loss Drug Sales Climbed

An analysis of federal payment data found Eli Lilly and Novo Nordisk paid over 250,000 US prescribers as GLP-1 weight loss drug sales grew.

Reason · Sep 10

Can a New Weight Loss Treatment Escape the Legal and Regulatory Thicket?

It’s Eli Lilly vs. RFK Jr. in a battle over the rules around retatrutide.

MarketBeat · Sep 4

Revolution Medicines Got Its Breakthrough—What Moves It Next?

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Barchart · Aug 31

A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today

Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.

Medical Daily · Aug 29

Mounjaro Can Now Be Prescribed to Lower Heart Attack and Stroke Risk in Adults with Type 2 Diabetes

FDA approved Mounjaro to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high risk.

The Independent UK · Aug 28

Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks

Heart disease is is the leading cause of death for people with Type 2 diabetes

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Government Intervention

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.